Houtan Noushmehr's academic training and research experience has provided him exposure to many different areas of science including human physiology & diseases, molecular biology, genetics and bioinformatics & biostatistics. During his doctoral training with Dr. Peter W. Laird, he gained new insight and understanding of the epigenetic changes associated with Glioblastoma multiforme, a primary brain tumor by applying my bioinformatics skill. Not only did this work lay the foundation for his scientific curiosity in the field of epigenetics (specifically DNA methylation), but also fulfilled an exciting collaborative experience. Dr. Noushmehr has participated in a number of analysis working groups within The Cancer Genome Atlas (TCGA), and led several brain cancer initiative to classify and evaluate the prognostication of DNA methylation, including a project that characterized the stemness signatures across 33 tumor types spanning more than 10,000 samples using DNA methylation and Expression. As a professor and researcher Dr. Noushmehr manages a team of bioinformatician within the Molecular Tumor Board at Henry Ford Cancer Institute. His goals are to advance our understanding of the genomics and epigenomics that define normal and disease states specifically cancer and to create a bioinformatic workflow to analyze and interpret genomic and epigenomic data from patient biopsies in order to offer guided therapy.